HomeCardiva Medical

Cardiva Medical

VASCADE MVP Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures Receives FDA Approval

VASCADE MVP System uses a simple and proprietary delivery system to place a collagen patch on the outside of each vessel puncture site following completion of the procedure.

Cardiva Medical to Present New Clinical Data on the VASCADE MVP System for Multi-Vessel Closure Following Electrophysiology Procedures

11/5/18: The late-breaking abstract will be presented at the American Heart Association Scientific Sessions 2018 meeting.

FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure

4/5/18: VASCADE has performed exceptionally well for our current patients, and this new indication will empower many physicians to use VASCADE for vein closure.

Cardiva Medical Brings Total Financing Round to $41 Million; Announces Sponsorship of AMBULATE Trial, First Vascular Closure Trial Targeted at High Growth Electrophysiology Procedures

Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing – bringing total equity and debt financing in the current round to $41 million. The additional financing exceeds previous commitments for this round and includes returning equity and debt investors – including PTV Healthcare Capital, Canepa Healthcare, and affiliates of Luther King Capital Management.